Predicting success of nerve blocks for pain relief in herpetic neuralgia
Predictors of Response to Ultrasound-Guided Thoracic Paravertebral Nerve Block in Patients With Herpetic Neuralgia
This study is testing what factors can help predict if nerve blocks will effectively relieve pain for adults with herpetic neuralgia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Banī Suwayf, Beni Suweif Governorate) |
| Trial ID | NCT06761924 on ClinicalTrials.gov |
What this trial studies
This study investigates the factors that predict the success of thoracic paravertebral nerve blocks (TPVB) in patients suffering from herpetic neuralgia. By examining demographic, clinical, and procedural variables, the research aims to enhance the effectiveness of TPVB and improve pain management strategies. The study focuses on adults aged 18 to 70 diagnosed with herpetic neuralgia, aiming to identify which patients are most likely to benefit from this intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 with a diagnosis of herpetic neuralgia and one dermatomal affection in the thoracic distribution.
Not a fit: Patients with contraindications to TPVB, severe comorbidities, or known allergies to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management strategies for patients suffering from herpetic neuralgia.
How similar studies have performed: Previous studies have shown that paravertebral nerve blocks can effectively treat acute pain in herpes zoster patients, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged from18 to 70 years * Diagnosed with herpetic neuralgia. * Able and willing to provide informed consent. * ASA I - II * One dermatomal affection * Thoracic distribution Exclusion Criteria: * Contraindications to TPVB as ( Infection at site of injection, empyema , coagulopathy and neoplastic lesion occupying the paravertebral space) * Known allergies to study medications (bupivacaine, Dexamethasone). * Severe comorbidities that could interfere with study participation.
Where this trial is running
Banī Suwayf, Beni Suweif Governorate
- Beni Suef University Hospital — Banī Suwayf, Beni Suweif Governorate, Egypt (Recruiting)
Study contacts
- Principal investigator: Dina M Fakhry, MD — Beni-Suef University
- Study coordinator: Dina M Fakhry, MD
- Email: drdina.mahmoud@med.bsu.edu.eg
- Phone: +201289998680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.